Healthcare Analyst

Wilfred Yuen

Healthcare analyst with 12+ years’ experience in both sell-side and buy-side leadership roles, with extensive experience IPO experience and a robust network of institutional investors and corporate executives. Coverage spans biopharma, biotech, CROs, devices, and health-tech stocks, delivered through with stock/sector/thematic reports, detailed financial models, and direct corporate access.

BeOne (ONC.US): 2Q Results Call Takeaway; 2026 Guidance Raised on Strength of Brukinsa; Next up ESMO

LEGN: 2Q26 Call Takeaways; 2026 Profitability on Track; Next up on LB2501 (In Vivo CAR-T) Updates

China Healthcare Weekly Wrap (27-31 July)

Hutchmed (13.HK): 1H26 Call Takeaway: 2026 Guidance Intact; 2H Catalysts: SAFFRON, ATTC BD, R&D Day

China Healthcare Weekly Wrap (20-24 July)

Equity Bottom-Up

<ul>
<li>2Q26 topline (RMB16.5bn) growing at 32% QoQ driven by Wuxi Chemistry (+35% QoQ to RMB14.4bn) thanks to strong growth from oligo &amp; peptide business TIDES (+105% QoQ to RMB4.88bn). </li>
<li>While 2026 revenue guidance raised by c.14%, it implies 2H26 revenue of RMB30.6bn or a HoH growth of 6%, which we believe is still conservative considering the strong 2Q26 momentum</li>
<li>See inside for detailed quarterly financial analysis for 1Q26 and 2Q26; Wuxi Apptec will host results call tomorrow 8am Beijing time</li>
</ul>


2Q26 topline (RMB16.5bn) growing at 32% QoQ driven by Wuxi Chemistry (+35% QoQ to RMB14.4bn) thanks to strong growth from oligo &amp; peptide business TIDES (+105% QoQ to RMB4.88bn). 
While 2026 revenue guidance raised by c.14%, it implies 2H26 revenue of RMB30.6bn or a HoH growth of 6%, which we believe is still conservative considering the strong 2Q26 momentum
See inside for detailed quarterly financial analysis for 1Q26 and 2Q26; Wuxi Apptec will host results call tomorrow 8am Beijing time


Wuxi Apptec (2359.HK): 2Q Beat on Strong QoQ Growth in TIDES; 2026 Topline Guidance Raised by C.14%

WuXi AppTec

Wuxi Apptec (2359.HK): 2Q Beat on Strong QoQ Growth in TIDES; 2026 Topline Guidance Raised by C.14%